Galera Therapeutics, Inc. (NASDAQ:GRTX) is a clinical stage biopharmaceutical company structured aorund the development and commercialization of therapeutics for transformation of radiotherapy in cancer. The company's lead product candidate is indicated as avasopasem manganese (GC4419), a small molecule dismutase mimetic. The completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. IThe firm is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer.
